Autopsy report · NCT02436512

Study to Assess Acute Vasodilation Response of Inhaled Nitric Oxide

“Inability meet enrollment in study population.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Geno LLC

Sponsor type

Industry

Conditions

Pulmonary Arterial Hypertension

Interventions

Inhaled Nitric Oxide

Participants

0

Sites

2

Countries

United States

Trials that died the same way

• Cardiogoniometry for Detecting Coronary Artery Disease by CT Angiography
  “Poor enrollment due to insufficient study support.” (81% match in meaning)
• Treatment of Type I Hepatorenal Syndrome (HRS) With Pentoxyfylline
  “Poor enrollment of study population” (80% match in meaning)
• Discharge Counseling and Medication Therapy Management (MTM) Services After Discharge for Heart Failure Patients
  “Unable to enroll and study intended patient population.” (79% match in meaning)
• The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD
  “Study subject enrollment difficulties” (77% match in meaning)
• Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma
  “Enrollment challenges, study not feasible” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.